Life Sciences IPOs Have Biggest Month in 13 Years, Burrill & Company says June 04, 2013 | Press Release
Thermo Fisher Scientific's $13.6 Billion Acquisition of Life Technologies Boosts Flagging M&A Numbers May 01, 2013 | Press Release
Burrill Securities Launches Institutional Breakthrough Series April 29, 2013 | Press ReleaseSee all News
Submit a Business PlanDo great things with us.Click here
Burrill & Company Investment Platform
Specific Industry Focus and Unique Characteristics
- Exclusive focus on life sciences
“life science only”
“all sectors of biotechnology” — human healthcare (Rx and Dx), devices, medical technology, nutraceuticals, agbio, industrial, enabling technologies
- Competitive advantages
Global prominence and reputation within biotech community
Large team supported by strategic corporate partners and world class advisors
Unique platform for generating deal flow and assessing the scientific, investment and commercial aspects of life science opportunities
Special skills to build value in portfolio companies
Global Reach, Geographically AgnosticBurrill & Company adheres to clearly stated policies and procedures that govern the administration of the deal flow, due diligence examination and the investment decision process. Specific Analysts/Associates are assigned who catalog each investment proposal delivered to Burrill & Company. A Managing Director, working closely with Director(s) and Associates/Analysts, is assigned to each investment proposal throughout the period that the proposal remains under active consideration.
Burrill senior management is responsible for directing the operations of the funds and the investment team meets weekly. The team is comprised of the CEO, the Managing Directors, Directors, Associates, Analysts and Secondees. Other representatives of the strategic partners who are expert in regulatory, legal, patent issues and scientific affairs frequently attend weekly investment meetings and assist in due diligence.
Burrill reviews an average of 100 deals per month, engaging in preliminary due diligence evaluation on approximately 30% of all proposals received and investing heavily in time and effort in approximately 10% of all proposals. Approximately 1% of all proposals that get delivered to the firm result in an actual commitment of funded capital.
Investment StrategyBurrill & Company invests in life science companies whose technologies and products are applicable across a wide range of life science sub-sectors: human healthcare therapeutics and diagnostics/devices; health/wellness; agricultural biotechnology; biofuels, and industrial biotechnology (biomaterials/bioprocesses).
In addition, to sector diversification, Burrill also diversifies across investment stage. In general, most of the investments are expected to be in the startup through mezzanine stage. The largest number of investments are targeted to Series A and B rounds, and we do invest in public entities.
Burrill principally invests in the United States and Europe, but has strategic interests globally. The average investment made by Burrill is $5-15 million over the life of any one company.
Burrill professionals almost always serve on the Board of Directors of each portfolio company, and assist with operational activities.